IXICO Provides an Update on New and Current Contracts

IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, today announces an update on contracts: 

·    Two new biopharmaceutical client contracts with combined value of over £1m

·    Award of a significant change order to Phase III Huntington’s disease contract worth c£0.9 million

·    Discontinuation of a study with no impact on FY19 revenue; reduction of contract revenue of £3.5m over the full term of the agreement to 2025

·    Confirms confidence in the current year market expectations and the outlook for next year

Read more…

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH